# CBD for Alcohol Use Disorders: An Updated Review Highlights Preclinical Promise and Human Nuance > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-for-alcohol-use-disorder-clinical-review/ > **Published:** 2026-09-17T17:58:34-04:00 | **Last Modified / Clinically Audited:** 2026-10-01T12:33:28-04:00 > **Clinical Summary:** Evidence-based clinical review of CBD for alcohol use disorder. Explore the gap between preclinical promise and human clinical trial outcomes. --- CED Clinical Relevance #78 Strong Synthesizes five years of expanded research, clarifying the critical divergence between robust animal models and null human clinical trials of CBD isolate. Clinical Insight | CED Clinic The widespread commercial enthusiasm surrounding cannabidiol has led many patients and wellness advocates to assume that CBD is a proven, ready-to-use therapy for alcohol use disorder. This comprehensive September 2026 review in Alcoholism: Clinical and Experimental Research delivers a critical reality check. While preclinical rodent models demonstrate that pure CBD isolate can reduce alcohol consumption, subsequent human clinical trials have yielded largely null results. To make genuine therapeutic progress, clinicians and researchers must distinguish between pure isolates and whole-plant formulations, address severe oral bioavailability limitations, and target specific patient subgroups rather than assuming broad, universal efficacy. Alcohol Use DisorderCannabidiol (CBD)PharmacokineticsAddiction Medicine[Harm Reduction](https://cedclinic.com/adolescent-cannabis-use-psychotic-disorders-risk/) AudiencePatients, Primary Care Physicians, Addiction Medicine Specialists, and Clinical Researchers Primary TopicCBD for Alcohol Use Disorder Source[Read the PubMed Record (PMID 42704305)](https://pubmed.ncbi.nlm.nih.gov/42704305/) A major September 2026 review synthesizes expanded research on cannabidiol for alcohol use disorder, revealing that while animal models showed reduced consumption, human clinical trials of CBD isolate remain largely null. What This Study Teaches Us This systematic review critically evaluates the surge in cannabinoid addiction research over the past five years. Its central lesson is that preclinical success in rodents does not automatically translate into clinical efficacy in people. While pure CBD isolate effectively curbed voluntary drinking in animal models, human randomized trials testing isolate have failed to show meaningful reductions in drinking volume. However, emerging observational human data and full-spectrum formulations with trace cannabinoids indicate that botanical complexity and formulation pharmacokinetics may be necessary to unlock clinical utility. Why This Matters Alcohol use disorder remains one of the leading drivers of preventable morbidity and mortality worldwide, yet existing FDA-approved pharmacotherapies are severely underutilized and demonstrate only modest clinical success. As patients increasingly turn to over-the-counter hemp and CBD products seeking self-directed harm reduction, clinicians need unvarnished, evidence-grounded facts. Without clear scientific guidance, patients risk relying on ineffective isolate doses or neglecting proven multidisciplinary recovery support. Study SnapshotStudy DesignNarrative systematic review synthesizing preclinical animal models, human randomized controlled trials, and observational studiesPopulationAdults diagnosed with alcohol use disorder across clinical trials, alongside validated rodent models of ethanol intakeInterventionsPurified cannabidiol isolate (oral capsules/solutions) compared with botanical and full-spectrum cannabinoid formulationsComparatorPlacebo controls, standard of care, and baseline drinking measures across synthesized trialsPrimary OutcomesAlcohol consumption volume, heavy drinking days, craving intensity, threat anticipation, withdrawal neurobiology, and hepatoprotectionKey ResultsHuman clinical trials of pure CBD isolate yielded largely null findings for drinking reduction; craving data remain inconsistent; full-spectrum extracts show exploratory promisePharmacokineticsPoor oral bioavailability (typically under 10 percent) severely blunts therapeutic exposure, requiring novel delivery routes and plasma level trackingFunding & DisclosuresResearch Society on Alcohol; published via Wiley Open Access; lead authors affiliated with University of Colorado Boulder and Anschutz Medical Campus Clinical Bottom Line Pure CBD isolate cannot currently be recommended as a standalone pharmacotherapy for alcohol use disorder based on existing human clinical trials. However, preclinical evidence for neuroprotection and withdrawal relief remains compelling, pointing toward the urgent need for optimized formulations and full-spectrum trials. The Growing Divergence Between Rodent Models and Human Realities Preclinical rodent investigations conducted over the past decade established an alluring hypothesis: animals administered CBD consistently reduced their self-administration of ethanol, resisted relapse cues, and demonstrated lower alcohol-induced neuroinflammation. These dramatic rodent findings catalyzed widespread clinical interest and fueled commercial marketing claims. However, as synthesized by Pince and colleagues, human randomized controlled trials translating this work have encountered stark roadblocks. When human participants with alcohol use disorder were administered purified oral CBD isolate, researchers observed largely null effects on primary drinking endpoints. Pure isolate failed to significantly diminish overall drinking days or total ethanol volume compared to placebo. The Bioavailability Hurdle and Formulation Paradox A major mechanical insight emphasized in this updated review centers on pharmacokinetics. Cannabidiol exhibits notoriously poor and erratic oral bioavailability, with extensive first-pass hepatic metabolism leaving only a fraction of an ingested dose biologically active in systemic circulation. Many human trials may simply have failed to achieve the sustained plasma concentrations required to engage central reward and stress circuits. Furthermore, emerging observational evidence highlights a formulation paradox. While synthetic or purified CBD isolate has repeatedly underperformed in human AUD trials, observational cohorts utilizing plant-derived, full-spectrum formulations, which include minor cannabinoids and trace levels of THC, have documented reductions in craving and drinking frequency. Whether this reflects botanical synergy or distinct pharmacological targets warrants rigorous, randomized evaluation. Beyond Consumption: Neuroprotection, Liver Health, and Withdrawal While drinking cessation is the traditional benchmark for regulatory approval, AUD causes systemic damage that extends far beyond immediate consumption habits. The review highlights robust preclinical data indicating that CBD protects against alcohol-induced hepatotoxicity, mitigating steatosis, lipid peroxidation, and inflammatory cytokine cascades in the liver. Additionally, CBD demonstrates neuroprotective properties in animal models subjected to binge ethanol exposure, attenuating cortical neurodegeneration and stabilizing autonomic tone during acute withdrawal. Although clinical trials verifying these organ-protective effects in humans remain scarce, they represent a vital secondary therapeutic frontier that could provide meaningful harm reduction even if absolute abstinence is not achieved. How Strong Is This Evidence? The evidence synthesized in this review occupies two starkly distinct tiers. Preclinical mechanistic evidence demonstrating anti-inflammatory, neuroprotective, and anti-drinking effects in animals is robust and methodologically consistent across multiple independent laboratories. In sharp contrast, human clinical evidence is currently modest and mixed, characterized by small sample sizes, brief intervention windows, and predominantly null outcomes in controlled trials evaluating purified CBD isolate. Where This Paper Deserves Skepticism Readers and clinicians must exercise substantial skepticism toward commercial narratives claiming CBD is an established treatment for alcoholism. Human clinical trials have simply not replicated the robust consumption reductions seen in rodents. Furthermore, existing human craving studies employ heterogeneous psychological paradigms that yield conflicting results, while oral dosing protocols rarely measure circulating plasma cannabinoid concentrations, leaving bioavailability as a confounding variable. What This Paper Does Not Show This review does NOT show that commercially available CBD gummies, tinctures, or isolate products effectively treat alcohol use disorder, reduce alcohol cravings, or prevent relapse in human patients. It does NOT show that CBD can safely replace medically supervised detoxification protocols for severe alcohol withdrawal, nor does it establish that over-the-counter products protect the human liver from chronic alcohol-induced cirrhosis. How This Fits With the Broader Clinical Conversation Alcohol use disorder affects more than 29 million Americans, yet fewer than two percent of diagnosed individuals receive evidence-based pharmacotherapies like acamprosate, naltrexone, or disulfiram. In this therapeutic vacuum, patients frequently turn to cannabinoids, either informally as a harm-reduction substitution strategy or based on wellness marketing. Dr. Karoly and colleagues at the University of Colorado have pioneered research examining real-world [cannabis use](https://cedclinic.com/cannabis-use-patterns-young-adults-social-health/) patterns among heavy drinkers. Their synthesis situates CBD within the broader landscape of addiction medicine, illustrating that while simplistic isolate monotherapy has fallen short, nuanced [cannabinoid science](https://cedclinic.com/cannabis-wellness-frontiers/), addressing sleep architecture, negative affect, and neuroinflammation, may still yield valuable adjunct tools when combined with comprehensive behavioral care. Dr. Caplan’s Take *In [clinical practice](https://cedclinic.com/shifting-public-attitudes-toward-cannabis/), I frequently speak with patients who are fighting to reduce their alcohol intake and hope that CBD will serve as an effortless silver bullet. This paper provides the rigorous, sober perspective that every clinician and patient needs to hear: when you give patients purified CBD isolate in an oral capsule, it simply does not perform miracles against alcohol use disorder.* *However, recognizing that pure isolate failed in trials does not mean cannabinoids have no role in alcohol recovery. When we look at real-world harm reduction, patients who thoughtfully incorporate whole-plant botanical formulations often report improvements in sleep latency, anxiety management, and evening restlessness, which are the exact vulnerabilities that drive evening drinking. The future of this field lies in personalized biobehavioral phenotyping and whole-plant delivery systems, not in oversimplified isolate marketing.* What a Careful Reader Should Take Away Preclinical enthusiasm must be tempered by human trial realities. While CBD isolate has repeatedly failed to reduce alcohol consumption in randomized human studies, research into whole-plant formulations, pharmacokinetic optimization, and organ-protective harm reduction remains an active, legitimate clinical frontier. Evidence Interpretation Guide Table of Contents - [How to Translate Emerging Cannabinoid Literature into Responsible Addiction Medicine](#How_to_Translate_Emerging_Cannabinoid_Literature_into_Responsible_Addiction_Medicine)[Four Principles for Evaluating Cannabinoids in Alcohol Use Disorder](#Four_Principles_for_Evaluating_Cannabinoids_in_Alcohol_Use_Disorder) - [Eight Perspectives on CBD in Alcohol Use Disorder](#Eight_Perspectives_on_CBD_in_Alcohol_Use_Disorder)[What This Evidence Means for Patients Seeking Support](#What_This_Evidence_Means_for_Patients_Seeking_Support) - [Clinical Guidance for Primary Care and Addiction Providers](#Clinical_Guidance_for_Primary_Care_and_Addiction_Providers) - [Methodological Roadmaps for Future Cannabinoid Trials](#Methodological_Roadmaps_for_Future_Cannabinoid_Trials) - [Navigating Expectations and Evidence for Families](#Navigating_Expectations_and_Evidence_for_Families) - [Addressing Health Fraud and Supplement Labeling Enforcement](#Addressing_Health_Fraud_and_Supplement_Labeling_Enforcement) - [Ethical Standards and Staff Education in Retail Cannabis](#Ethical_Standards_and_Staff_Education_in_Retail_Cannabis) - [Evaluating Valid Critiques of the Cannabinoid Narrative](#Evaluating_Valid_Critiques_of_the_Cannabinoid_Narrative) - [Population Health and Harm Reduction Frameworks](#Population_Health_and_Harm_Reduction_Frameworks) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## How to Translate Emerging Cannabinoid Literature into Responsible Addiction Medicine Interpreting addiction pharmacotherapy requires rigorous distinction between mechanistic hypotheses and demonstrable clinical outcomes. When media outlets and supplement manufacturers report on cannabinoid research, they routinely conflate rodent studies with human clinical validation. To help patients and clinicians evaluate new findings without falling prey to premature hype or unwarranted cynicism, we have organized the key principles of this updated review into a practical evaluation framework. ### Four Principles for Evaluating Cannabinoids in Alcohol Use Disorder **1. Isolate vs. Botanical Formulations**Never assume all CBD products act identically. Controlled trials using purified isolate have yielded largely null human results, whereas observational studies hint that full-spectrum extracts with minor cannabinoids may exert different neurobehavioral effects. **2. The Bioavailability Imperative**Swallowed CBD suffers from extensive first-pass metabolism, with less than 10 percent reaching systemic circulation. Without verified blood levels or specialized delivery technologies, negative trial outcomes may simply reflect inadequate tissue exposure. **3. Consumption Versus Harm Reduction**Total abstinence is not the sole clinical metric. Even if a cannabinoid does not immediately extinguish drinking urges, demonstrated protection against neurodegeneration or hepatic steatosis represents clinically meaningful harm reduction. **4. Personalized Biobehavioral Phenotyping**Addiction is deeply heterogeneous. Future successful therapies will identify specific patient subgroups, such as individuals whose drinking is primarily driven by anxiety or hyperarousal, who are biologically predisposed to benefit from endocannabinoid modulation. The Clinician’s Practical Question Should I recommend or endorse CBD for my patients struggling with alcohol use disorder? The clinical answer is straightforward: no clinician should recommend CBD as a primary, standalone treatment for AUD. FDA-approved medications and evidence-based psychotherapy remain first-line care. However, if a patient is already utilizing CBD for related symptoms like anxiety or insomnia, clinicians should evaluate product purity, review potential cytochrome P450 drug interactions, and ensure the patient is not neglecting comprehensive addiction care. What Patients Most Frequently Ask ‘Can I take CBD oil to help stop drinking?’ While you may hear anecdotal stories from friends or social media, rigorous clinical trials have shown that standard CBD isolate oils do not reliably reduce alcohol intake or eliminate cravings in human patients. While CBD is generally well tolerated, relying on it instead of proven medical care can put your recovery at risk. Talk openly with your doctor about comprehensive medical and behavioral strategies. The Bottom Line CBD is not a clinically validated cure or replacement for standard alcohol use disorder treatments. Ongoing research must prioritize advanced delivery systems and rigorous full-spectrum trials before clinical adoption can be justified. CED Perspective Lens ## Eight Perspectives on CBD in Alcohol Use Disorder Evaluating what updated clinical evidence means across different stakeholder viewpoints without extrapolating beyond verified facts. Lens OverviewThe debate surrounding CBD for alcohol use disorder involves distinct practical considerations for patients, physicians, neuroscientists, family members, regulators, dispensaries, academic skeptics, and public health officials. #### What This Evidence Means for Patients Seeking Support For individuals seeking to reduce or quit drinking, this review offers essential clarity and caution. While over-the-counter marketing frequently promotes CBD oil as a natural remedy for addiction cravings, controlled clinical studies demonstrate that pure oral CBD isolate does not significantly decrease alcohol intake. Patients who find that botanical CBD products ease their evening anxiety, restlessness, or insomnia should understand that symptom relief does not equate to an addiction cure. Proven medical therapies, counseling, and peer support remain the indispensable foundation of successful, long-term alcohol recovery. Lens takeawayPatients should not rely on CBD isolate as a substitute for proven medical and behavioral alcohol addiction therapies. #### Clinical Guidance for Primary Care and Addiction Providers Physicians and addiction specialists must proactively initiate conversations about cannabinoid self-treatment. Many patients quietly experiment with over-the-counter CBD formulations without informing their providers, assuming that hemp derivatives carry no clinical risks or drug interactions. Clinicians should explain the difference between rodent studies and human clinical trials, screen for cytochrome P450 interactions, and emphasize first-line FDA-approved AUD medications. Cannabinoid discussions should foster an open, nonjudgmental dialogue focused on overall harm reduction and evidence-based treatment adherence. Lens takeawayClinicians must educate patients on the absence of human trial efficacy for isolate while maintaining nonjudgmental harm-reduction dialogue. #### Methodological Roadmaps for Future Cannabinoid Trials For clinical investigators, this narrative review highlights crucial methodological lessons. Past trials frequently relied on fixed oral dosing without measuring circulating plasma CBD levels, leaving it unclear whether negative findings reflected true biological failure or inadequate systemic absorption. Future research protocols must integrate biobehavioral phenotyping, pharmacokinetic tracking, and objective biomarker verification. Exploring botanical full-spectrum extracts and sublingual or inhalational delivery routes will be critical to resolving the discrepancies observed between preclinical models and human clinical trials. Lens takeawayResearchers must incorporate plasma level measurements, advanced delivery formulations, and patient phenotyping in upcoming clinical trials. #### Navigating Expectations and Evidence for Families Family members and caregivers supporting a loved one with alcohol dependence often feel overwhelmed and eager for non-stigmatizing, accessible solutions. It is completely understandable that widely advertised wellness remedies like CBD appear attractive and gentle compared to traditional rehabilitation routes. However, families should understand that CBD isolate is not an established clinical remedy for alcohol addiction. Encouraging a loved one to seek comprehensive psychiatric, medical, and community-based recovery resources remains the safest and most effective way to provide meaningful, durable support. Lens takeawayCaregivers should guide loved ones toward evidence-based multidisciplinary recovery programs rather than unproven commercial supplement regimens. #### Addressing Health Fraud and Supplement Labeling Enforcement Regulatory bodies including the FDA and FTC face an ongoing challenge regarding unsubstantiated therapeutic claims. Commercial vendors frequently cite preclinical rodent studies to market CBD tinctures as sobriety aids, misleading vulnerable consumers who are actively struggling with substance dependence. Clear regulatory boundaries and aggressive enforcement against deceptive addiction treatment marketing are essential to protect consumer health. Simultaneously, regulatory frameworks must facilitate legitimate investigational drug development to evaluate standardized botanical cannabinoid formulations through formal approval pathways. Lens takeawayRegulators must curb deceptive addiction-cure marketing while establishing clear pathways for rigorously tested pharmaceutical cannabinoid formulations. #### Ethical Standards and Staff Education in Retail Cannabis Cannabis retailers, dispensaries, and brand manufacturers operate on the front lines of consumer engagement. Staff members frequently encounter patrons asking for products to help curb alcohol consumption or ease uncomfortable withdrawal symptoms. Dispensary personnel have an ethical obligation not to make medical claims or suggest that CBD products can treat alcoholism. Investing in evidence-based staff education ensures that retail teams provide accurate information and responsibly direct individuals toward licensed healthcare professionals. Lens takeawayDispensary staff must strictly avoid presenting CBD products as addiction cures and direct inquiring customers to licensed medical providers. #### Evaluating Valid Critiques of the Cannabinoid Narrative Academic skeptics have long contended that the clinical potential of cannabidiol was prematurely overhyped based on rodent models with limited translational validity. The predominantly null human clinical trial results documented in this review provide substantial support for that critical perspective. Acknowledging these legitimate critiques does not dismiss cannabinoid science, but grounds it in necessary rigor. Enthusiasts must accept that preclinical enthusiasm cannot substitute for rigorous human data, and skepticism serves as an essential safeguard against unscientific clinical adoption. Lens takeawayScientific skepticism correctly identifies that animal addiction models have failed to translate into clinical efficacy in human trials. #### Population Health and Harm Reduction Frameworks From a broader public health standpoint, alcohol misuse continues to generate immense socioeconomic costs and severe chronic disease burdens across diverse communities. Public health agencies must provide transparent, unvarnished public education regarding what over-the-counter cannabinoids can and cannot accomplish for affected populations. Harm-reduction frameworks should embrace innovative scientific research while emphasizing verified clinical interventions. Expanding public access to underutilized FDA-approved addiction medications while funding rigorous clinical trials will yield far greater health dividends than unguided commercial supplement experimentation. Lens takeawayPublic health strategies must expand access to proven addiction medications while financing rigorous, objective cannabinoid clinical research. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=CBD+for+Alcohol+Use+Disorders%3A+An+Updated+Review+Highlights+Preclinical+Promise+and+Human+Nuance&url=https%3A%2F%2Fcedclinic.com%2Fcbd-for-alcohol-use-disorder-clinical-review%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcbd-for-alcohol-use-disorder-clinical-review%2F) [BlueSky](https://bsky.app/intent/compose?text=CBD+for+Alcohol+Use+Disorders%3A+An+Updated+Review+Highlights+Preclinical+Promise+and+Human+Nuance%20https%3A%2F%2Fcedclinic.com%2Fcbd-for-alcohol-use-disorder-clinical-review%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Alcohol: Clinical and Experimental Research (Hoboken) – Pince et al. (September 2026)](https://pubmed.ncbi.nlm.nih.gov/42704305/) Related Reading at CED ClinicContinue exploring the evidence[Comparative Transcriptome Analysis Reveals Novel Addiction and Cannabinoid Pathways](https://cedclinic.com/cannabis-news-and-regulatory-roundup-comparative-transcriptome-analysis-sep-2026/) Examine how molecular signaling and receptor transcriptomics inform our understanding of substance use and endocannabinoid modulation. [Explore the genetic evidence](https://cedclinic.com/cannabis-news-and-regulatory-roundup-comparative-transcriptome-analysis-sep-2026/)[Cannabis Compounds CBD and CBG for Hepatic and Metabolic Health](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Review the preclinical and emerging clinical science evaluating cannabinoid hepatoprotection against steatosis and inflammation. [Read the liver health review](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/)[Understanding the Endocannabinoid System in Adolescent Coping and Substance Risk](https://cedclinic.com/cannabis-use-in-adolescents-understanding-endocannabinoid-systems-role/) Investigate the neurobiological mechanisms linking anxiety, depressive symptoms, and substance coping behaviors. [Examine coping pathways](https://cedclinic.com/cannabis-use-in-adolescents-understanding-endocannabinoid-systems-role/) ## Frequently Asked Questions Can CBD cure or treat alcohol use disorder? No. Based on current scientific evidence, CBD is not an approved or proven cure for alcohol use disorder. Human clinical trials evaluating pure CBD isolate have yielded largely null results for reducing alcohol consumption. Why did CBD show promise in animals if it failed in human trials? Rodent models of voluntary drinking differ significantly from human alcohol addiction. Factors such as poor human oral bioavailability, complex psychological drivers, and distinct metabolic pathways often cause preclinical findings to fail in human translation. Does CBD reduce cravings for alcohol? Findings on alcohol craving remain inconsistent across studies. While some preclinical and small observational reports showed modest craving reductions, human randomized trials using CBD isolate have not consistently demonstrated meaningful craving suppression. Is full-spectrum CBD better than CBD isolate for alcohol use disorder? Observational research suggests full-spectrum products containing minor cannabinoids and trace THC may have different neurobehavioral effects than pure isolate. However, these formulations have not yet been validated in randomized controlled trials for AUD. Can CBD help with alcohol withdrawal symptoms? Preclinical animal models show that CBD can reduce withdrawal-induced seizures, autonomic hyperactivity, and neuroinflammation. However, clinical evidence in humans is minimal, and CBD should never replace medically supervised alcohol detoxification. Does CBD protect the liver from alcohol-induced damage? Animal studies indicate that CBD possesses antioxidant and anti-inflammatory properties that reduce hepatic steatosis and injury from binge alcohol exposure. Human clinical trials confirming these protective liver effects are currently lacking. What is the problem with oral CBD bioavailability? When CBD is swallowed, it undergoes extensive first-pass metabolism in the digestive tract and liver, leaving less than 10 percent to enter the bloodstream. This low absorption may explain why standard oral doses failed in clinical trials. Can I use CBD alongside standard alcohol medications like naltrexone? CBD can inhibit cytochrome P450 liver enzymes, which may alter the metabolism of other medications. Patients should always consult their physician before combining CBD with FDA-approved addiction pharmacotherapies. What should a patient do if they are struggling with alcohol intake? Patients should seek evaluation from a qualified healthcare professional or addiction specialist. First-line care includes evidence-based therapies like cognitive behavioral therapy and FDA-approved medications such as naltrexone or acamprosate. What kind of research is needed to determine if CBD has a future in AUD? Future research requires rigorous, randomized clinical trials that test standardized botanical formulations, utilize enhanced [delivery methods](https://cedclinic.com/state-ban-smokable-cannabis-impact-central-texas/) to overcome poor bioavailability, and measure circulating blood cannabinoid concentrations. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).